CreativeOne Wealth LLC Has $750,000 Holdings in CVS Health Co. (NYSE:CVS)

CreativeOne Wealth LLC boosted its position in shares of CVS Health Co. (NYSE:CVS) by 21.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,414 shares of the pharmacy operator’s stock after acquiring an additional 1,688 shares during the period. CreativeOne Wealth LLC’s holdings in CVS Health were worth $750,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Delap Wealth Advisory LLC acquired a new position in CVS Health in the first quarter valued at about $717,000. EntryPoint Capital LLC boosted its holdings in shares of CVS Health by 127.5% in the 1st quarter. EntryPoint Capital LLC now owns 1,397 shares of the pharmacy operator’s stock worth $111,000 after acquiring an additional 783 shares in the last quarter. Vident Advisory LLC increased its holdings in CVS Health by 15.1% during the 1st quarter. Vident Advisory LLC now owns 371,983 shares of the pharmacy operator’s stock valued at $29,669,000 after purchasing an additional 48,785 shares in the last quarter. Fayez Sarofim & Co raised its stake in shares of CVS Health by 4.7% in the first quarter. Fayez Sarofim & Co now owns 11,354 shares of the pharmacy operator’s stock worth $906,000 after acquiring an additional 513 shares during the last quarter. Finally, LGT Group Foundation lifted its position in CVS Health by 3.1% during the 1st quarter. LGT Group Foundation now owns 24,203 shares of the pharmacy operator’s stock valued at $1,930,000 after purchasing an additional 736 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Up 4.0 %

Shares of NYSE:CVS traded up $2.35 on Friday, hitting $61.00. 14,553,173 shares of the company’s stock were exchanged, compared to its average volume of 7,959,074. The stock has a market capitalization of $76.58 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52. CVS Health Co. has a 12 month low of $52.77 and a 12 month high of $83.25. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. The business’s 50 day simple moving average is $58.85 and its two-hundred day simple moving average is $67.47.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The company had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.20 EPS. Analysts anticipate that CVS Health Co. will post 7 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Monday, July 22nd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.36%. The ex-dividend date is Monday, July 22nd. CVS Health’s dividend payout ratio is 46.75%.

Analyst Ratings Changes

Several equities analysts recently commented on CVS shares. Leerink Partnrs downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 1st. Robert W. Baird assumed coverage on shares of CVS Health in a research report on Thursday, May 30th. They issued a “neutral” rating and a $61.00 target price for the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $58.00 price target on shares of CVS Health in a research report on Tuesday. Mizuho cut their target price on CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Thursday, May 2nd. Finally, Barclays reduced their target price on CVS Health from $78.00 to $63.00 and set an “equal weight” rating on the stock in a report on Thursday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $75.05.

Insider Transactions at CVS Health

In other news, Director Edward J. Ludwig acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was purchased at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the acquisition, the director now directly owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.24% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.